Trial Profile
An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Clovis Oncology [CEASED]
- 16 Mar 2019 Results of Part 1 of the study, presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 20 Feb 2019 Status changed from active, no longer recruiting to completed.
- 19 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.